Skip to main content

Global X Genomics & Biotechnology ETF (GNOM)

NASDAQ: GNOM · IEX Real-Time Price · USD
21.65 -0.01 (-0.05%)
Oct 22, 2021 4:00 PM EDT - Market closed
Assets$269.64M
NAV$21.67
Expense Ratio0.50%
PE Ratio-24.19
Shares Out12.44M
Dividend (ttm)$0.03
Dividend Yield0.15%
Ex-Dividend DateDec 30, 2020
1-Year Return
-
Volume42,689
Open21.68
Previous Close21.66
Day's Range21.45 - 21.69
52-Week Low17.78
52-Week High28.45
Beta1.03
Holdings40
Inception DateApr 5, 2019

About GNOM

The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index (underlying index). The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, Genomics & Biotechnology Companies), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.

Asset ClassEquity
RegionGlobal
IssuerGlobal X Mgt
Stock ExchangeNASDAQ
Ticker SymbolGNOM
Index TrackedSolactive Genomics Index

Top 10 Holdings

49.55% of assets
NameSymbolWeight
Intellia TherapeuticsNTLA6.83%
Alnylam PharmaceuticalsALNY6.19%
Agilent TechnologiesA5.06%
Sarepta TherapeuticsSRPT5.02%
GENSCRIPT BIOTECH CORP1548.HK4.98%
QiagenQGEN4.77%
Blueprint MedicinesBPMC4.51%
NateraNTRA4.31%
BioMarin PharmaceuticalBMRN4.05%
Arrowhead PharmaceuticalsARWR3.83%
View More Holdings

Dividends

Ex-DividendAmountPay Date
Jun 29, 2021$0.000Jul 8, 2021
Dec 30, 2020$0.0324Jan 8, 2021
Full Dividend History

News

Healthcare ETFs to Gain on $65-Billion Pandemic Protection Plan

The Biden administration recently offered a $65 billion plan that U.S. officials say is aimed at combating the biological threats after the COVID-19 pandemic goes away.

Other symbols:GERMIHEVIRSXHE
1 month ago - Zacks Investment Research

How Are Genomics ETFs Responding to Q2 Earnings?

Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.

2 months ago - Zacks Investment Research

Snag Next-Generation Tech Exposure with This Genomics ETF

ETF investors looking to get in on the next generation of medical technology may want to give the Global X Genomics & Biotechnology ETF (GNOM) a closer look. Genomic sequencing is already playing a pivo...

3 months ago - ETF Trends

A Comprehensive Guide to Genomic ETFs

Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.

3 months ago - Zacks Investment Research

Genomics ETFs Surge on a Major Breakthrough in CRISPR Study

The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.

3 months ago - Zacks Investment Research

4 ETF Areas Surged Last Week

These four ETF areas were winners last week.

Other symbols:AMLPAMZABDRYBTECBUG
4 months ago - Zacks Investment Research

Top-Performing Biotech ETFs of Last Week

Investors may want to tap the bullishness in the sector with the best biotech ETFs of last week.

4 months ago - Zacks Investment Research

3 Biotech ETFs That Could Double Your Money by 2025 With Zero Effort

In a sector where picking individual stocks is a high-risk, high-reward strategy, the diversification of exchange-traded funds can be highly appealing.

Other symbols:INDAXBI
4 months ago - The Motley Fool

Biotech ETFs Surge on Biogen's Alzheimer Drug Approval

The approval for Biogen's Alzheimer's disease treatment has spread strong optimism, with many investors pulling in capital to this high growth and high beta sector.

Other symbols:BBCPBESBIOXBI
4 months ago - Zacks Investment Research

ETF Battles: ARKG Vs GNOM

Which biotech/genomics ETF is the better play?

Other symbols:ARKG
4 months ago - ETFcom

Can Global X's GNOM Be the Next Big ETF?

Genomics could be the next big thing in the biotechnology space. Similarly, the Global X Genomics & Biotechnology ETF (GNOM) could be the next big fund, and is already up 10% to start the new year.

9 months ago - ETF Trends

Top-Performing Biotech ETFs Amid the COVID-19 Crisis

The coronavirus pandemic triggered a race to introduce vaccine and treatment, thereby opening up new investing opportunities in the biotech sector in 2020.

Other symbols:ARKGBTECIDNAXBI
9 months ago - Zacks Investment Research

Get On Board a Growing Biotech Industry With the GNOM ETF

It's one thing to discuss the economics of investing in the biotech sector, but it's another to discuss genomics. The sub-sector of the biotech industry has seen strong growth as evidenced by the over 6...

10 months ago - ETF Trends

Healthcare ETFs: Winners & Losers in the Light of U.S. Election

The coronavirus vaccine development effort has put the spotlight on the U.S. healthcare sector in recent months.

Other symbols:CNBSIHEIHFIHIPJPXHE
1 year ago - Zacks Investment Research

Why You Should Invest in Genomics ETFs

Genomics ETFs have surged of late; here's why

Other symbols:ARKGIDNA
1 year ago - Zacks Investment Research

Top Sector ETFs From Wall Street's Best Week in 3 Months

Last week was cheery for Wall Street, with the S&P 500 and Nasdaq recording their best weekly advancement since July.

Other symbols:AMZATANTHCXXSD
1 year ago - Zacks Investment Research

Genomics ETFs Surge on Nobel Prize for Gene-Editing Pioneers

The announcement of the 2020 Nobel Prize winners for Chemistry has successfully brought investor attention to the gene-editing space.

Other symbols:ARKGIDNAPBE
1 year ago - Zacks Investment Research

Buy the Dip With These ETFs Under $20

The recent market rout led by the tech selloff has provided investors a great opportunity to tap the stocks under $20.

Other symbols:BETZEDOCICLNIEZ
1 year ago - Zacks Investment Research

Jay Jacobs: These High-Growth ETF Themes Have Seen Triple-Digit Returns In Coronavirus Rally

Jay Jacobs, SVP and head of research and strategy at Global X ETFs, joined the podcast this week to discuss thematic investing and the new Global X Telehealth ETF (EDOC). Plus, we take a look at two ETF...

Other symbols:SNSR
1 year ago - Investors Business Daily

The Genomics Market is Poised for Growth Through 2025

Disruptive technology is always an interesting play for investors to consider and the genomics market is one to watch closely. According to the “Genomics Market – Growth, Trends, and Forecasts (2020-202...

Other symbols:ARKG
1 year ago - ETF Trends

Three tech subgroups can keep climbing despite the sector's record run, ETF analyst says

Investors should consider buying into genomics, cloud computing and video gaming ETFs as tech trades near records, Global X's Jay Jacobs says.

Other symbols:CLOUHERORYTVGTXLK
1 year ago - CNBC

Biotech ETFs Surge After Invitae Acquires ArcherDX

Biotechnology sector-related exchange traded funds were among the leaders on Monday after Invitae Corp. (NYSE: NVTA) announced a $1.4 billion deal for ArcherDX, potentially bolstering the genetic inform...

Other symbols:ARKGXBI
1 year ago - ETF Trends

A Genomics ETF at the Center of the Coronavirus Fight

In the scramble to develop a Coronavirus vaccine, genomics investments are receiving renewed attention and rewarding investors in the process. Those sentiments are applicable to the Global X Genomics & ...

1 year ago - ETF Trends

ETFs Under $20 From 5 Hottest Zones

Let us dig into some of the ETFs that are below $20 and are from the hottest areas currently. These low-priced ETFs could lead to huge gains in the coming months.

Other symbols:IEZKBWDSDIVSILJ
1 year ago - Zacks Investment Research

3 Genomics ETFs Worth Jumping For

The scramble to bring a coronavirus vaccine to market is lifting the health care sector this year as a slew of biotechnology and other, more nuanced exchange-traded funds targeting the group are deliver...

Other symbols:ARKG
1 year ago - Benzinga